Filing Flows › Angiodynamics (ANGO) › Q4 FY26
Angiodynamics (ANGO) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Jul 14, 2026
Angiodynamics (ANGO) reported revenue of $86.6M for the fourth quarter fiscal 2026 (Q4 FY26), +8% from a year earlier and +10% from the quarter before. Operating margin was -11.8%, net loss $11.4M (13.2% of revenue).
Angiodynamics, Q4 FY26: revenue $86.6M (+8% year over year), operating margin -11.8%, net loss $11.4M, operating cash flow $17.5M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $86.6M | +10% | +8% |
| Operating profit | −$10.2M | — | — |
| Net earnings | −$11.4M | — | — |
| Operating cash flow | $17.5M | — | -7% |
| Free cash flow | $17.0M | — | -6% |
What changed
Revenue was $86.6M in Q4 FY26, up 8% year over year and up 10% from the previous quarter.
Gross margin was 54.0%, up 1.3 points from Q4 FY25. Operating costs exceeded revenue by $10.2M, an operating margin of -11.8%. Operating expenses grew 19% against revenue growth of 8%. The fastest-growing cost line was Other operating costs (+56%). The quarter ended with a net loss of $11.4M, wider than the previous quarter's $8.1M loss.
Operating cash flow was $17.5M (down 7% year over year). Non-cash charges added back $5.6M of depreciation and amortization and $3.9M of share-based compensation. Working capital and other items added $19.3M. Capital expenditures of $413K left free cash flow of $17.0M.
Questions
What was Angiodynamics' revenue in the fourth quarter fiscal 2026?
Angiodynamics (ANGO) reported revenue of $86.6M for the fourth quarter fiscal 2026 (Q4 FY26), +8% from a year earlier and +10% from the quarter before.
Was Angiodynamics profitable in the fourth quarter fiscal 2026?
Operating loss was $10.2M (-11.8% of revenue) and net loss $11.4M.
Source: Angiodynamics 10-K on SEC EDGAR.